Exploring Innovative Therapies

NeuroSigma, Inc. is developing trigeminal nerve stimulation (TNS) for a variety of disorders, including epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD) Lennox-Gastaut syndrome (LGS) and traumatic brain injury (TBI). NeuroSigma’s unique TNS technology can be delivered via the non-invasive Monarch external trigeminal nerve stimulation (eTNS™) system or the minimally-invasive subcutaneous trigeminal nerve stimulation (sTNS™) system which is currently under development.

The Monarch eTNS system is easy to use and convenient.

This cell phone sized device is now available as adjunctive treatment of epilepsy and depression in the European Union and Canada and as and adjunctive treatment for epilepsy in Australia.

Learn More

CAUTION: In the United States, both eTNS and sTNS are investigational devices and are limited by Federal (or United States) law to investigational use.

Latest News

April 23, 2019 NeuroSigma Announces FDA Clearance of Monarch eTNS System as First Non-Drug Treatment for Pediatric ADHD

December 6, 2017 Bioelectronic medicine is a fast growing alternative to drugs

October 30, 2017 UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD

December 10, 2015 Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

November 16, 2015 NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

May 4, 2015 NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

January 6, 2015 FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation

January 5, 2015 UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System

November 19, 2014 NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression

November 17, 2014 NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

November 3, 2014 NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

October 21, 2014 NeuroSigma Receives Notice of Allowance of U.S. Patent Application

October 15, 2014 NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

August 26, 2014 NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

August 25, 2014 U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

July 22, 2014 Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

July 9, 2014 NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

Learn More